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Mapping routine measles vaccination in  
low- and middle-income countries
Local Burden of Disease Vaccine Coverage Collaborators*
The safe, highly effective measles vaccine has been recommended globally since 1974, 
yet in 2017 there were more than 17 million cases of measles and 83,400 deaths in 
children under 5 years old, and more than 99% of both occurred in low- and 
middle-income countries (LMICs)1–4. Globally comparable, annual, local estimates of 
routine first-dose measles-containing vaccine (MCV1) coverage are critical for 
understanding geographically precise immunity patterns, progress towards the 
targets of the Global Vaccine Action Plan (GVAP), and high-risk areas amid disruptions 
to vaccination programmes caused by coronavirus disease 2019 (COVID-19)5–8. Here 
we generated annual estimates of routine childhood MCV1 coverage at 5 × 5-km2 pixel 
and second administrative levels from 2000 to 2019 in 101 LMICs, quantified 
geographical inequality and assessed vaccination status by geographical remoteness. 
After widespread MCV1 gains from 2000 to 2010, coverage regressed in more than 
half of the districts between 2010 and 2019, leaving many LMICs far from the GVAP 
goal of 80% coverage in all districts by 2019. MCV1 coverage was lower in rural than in 
urban locations, although a larger proportion of unvaccinated children overall lived in 
urban locations; strategies to provide essential vaccination services should address 
both geographical contexts. These results provide a tool for decision-makers to 
strengthen routine MCV1 immunization programmes and provide equitable disease 
protection for all children.
The safe, highly effective vaccine against measles has been recom-
mended since 1974 by the Expanded Programme on Immunization 
of the WHO (World Health Organization)1–3. A single valid dose of 
any MCV is approximately 93% effective in providing individuals 
with lifelong protection from measles1. Still, in 2017, there were an 
estimated 17,767,037 new global cases and 83,439 deaths attributa-
ble to measles in children under 5 years old4. Although high-income 
regions, such as the USA and Europe, have recently started expe-
riencing extended measles outbreaks due to a lapse in vaccina-
tion coverage, more than 99% of cases and deaths still occur in 
LMICs4,9.
Low vaccination rates and increasing vaccine hesitancy10–12 contrib-
ute to the persistence of measles as a major cause of childhood mor-
bidity and mortality. National-level MCV1 estimates from the Global 
Burden of Diseases, Injuries and Risk Factors Study (GBD) 2019 identi-
fied only 72 out of 204 countries in which routine coverage reached 
approximate herd immunity targets (≥95%) in 2019, and global MCV1 
coverage4,13 was 84.2%. Even in countries with high national coverage, 
these estimates mask important subnational heterogeneities that 
may sustain ongoing disease transmission and increase the risk of 
outbreaks14–17, especially in light of the current service disruptions 
associated with the COVID-19 pandemic7,8. Global vaccination initia-
tives, such as the GVAP and Immunization Agenda 2030, recognize the 
importance of eliminating subnational coverage disparities, aiming 
for at least 90% of the target population in every country and 80% in 
every district to be covered5,6.
 
Subnational routine MCV1 coverage
Since 2016, the WHO and UNICEF have collected subnational cov-
erage data through their annual Joint Reporting process, although 
poor data quality and biases currently limit the use of administrative 
data to track progress towards GVAP targets18–20. For the 101 countries 
included in this study, 91 reported subnational data in 2018 in a total of 
11,311 subnational geographical units. Of these countries, 71 reported 
MCV1 coverage greater than 100% in at least one unit and 55 reported 
such coverage in at least a quarter of units. Although researchers have 
estimated subnational MCV1 coverage in select countries or years 
for which there have been reliable surveys, to date, no comprehen-
sive analysis of all available vaccine coverage data to produce sub-
national estimates of MCV1 coverage annually in all LMICs has been 
undertaken21–24.
Building from our previous work mapping diphtheria–tetanus–
pertussis vaccine coverage in Africa14, here we present mapped 
high-spatial-resolution estimates of routine MCV1 coverage across 101 
LMICs from 2000 to 2019, aggregated to policy-relevant second-level 
administrative units (hereafter districts). Using geolocated data on 
MCV1 coverage from 354 household-based surveys representing 
approximately 1.70 million children and a suite of environmental, 
sociodemographic and health-related geospatial and national-level 
covariates, we extended model-based geostatistical methods that 
have been used to map child mortality and its main components 
and risk factors25–28 to predict MCV1 coverage and uncertainty 
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(Extended Data Figs. 1, 2), while calibrating estimates to results from 
GBD 2019. Using these estimates, we assessed trends in geographical 
inequality, progress towards global targets and differential vaccination 
status by geographical remoteness.
Tracking uneven progress
Despite marked global progress between 2000 and 2019, considerable 
inequalities in routine MCV1 coverage persist, both between and within 
countries (Fig. 1, Extended Data Figs. 3–7, see also our visualization 
tool (https://vizhub.healthdata.org/lbd/mcv)). MCV1 coverage among 
children living in the 101 countries included in this study was 65.6% (95% 
uncertainty interval, 64.2–67.1%) in 2000 and 81.0% (95% uncertainty 
interval, 79.2–82.7%) in 2019. Coverage increased at the national level 
in 69.9% (95% uncertainty interval, 64.4–75.2%) of countries between 
2000 and 2019 and in 57.4% (95% uncertainty interval, 50.4–64.6%) of 
districts (n = 20,795 districts).
The three districts with the lowest MCV1 coverage in 2000 were 
located in Hari Rasu, Ethiopia (4.0% (95% uncertainty interval, 1.1–
9.7%)), Gabi Rasu, Ethiopia (4.8% (95% uncertainty interval, 1.4–11.4%)), 
and Isa, Nigeria (4.9% (95% uncertainty interval, 1.5–10.8%)). In 2000, 
60 districts had a coverage below 10%; there was one such district 
in 2019. The three lowest-coverage districts in 2019 were all located 
in Afghanistan: Poruns (9.2% (95% uncertainty interval, 2.0–25.5%)), 
Wama (12.1% (95% uncertainty interval, 2.8–32.6%)) and Waygal (12.7% 
(95% uncertainty interval, 3.0–34.2%)).
In the period from 2000 to 2010, there were substantial increases in 
coverage and progress towards reducing subnational heterogeneity. 
The period from 2010 to 2019, however, showed slowing progress and, 
in some cases, regression of coverage compared to the 2000–2010 
period (Fig. 2). Between 2000 and 2010, 70.5% (95% uncertainty inter-
val, 66.0–75.4%) of districts increased coverage, but between 2010 
and 2019, coverage increased in only 40.1% (95% uncertainty interval, 
34.2–46.9%) of districts (Extended Data Fig. 8). This finding persists 
even when accounting for the starting level of coverage (Supplementary 
Information section 2.3).
Although district-level MCV1 coverage generally increased between 
2000 and 2019, further gains are required to reach both 80% and 95% key 
coverage targets (Extended Data Fig. 9). In 2000, 38.4% of districts had a 
high probability (>95% posterior probability) of reaching the GVAP target 
of 80% district-level MCV1 coverage, which remained stagnant at 33.2% 
of districts in 2019. Only 15 countries had a high probability of reaching 
the GVAP target of greater than 80% district-level coverage in all districts.
Quantifying geographical inequalities
To further assess the effect of geographical heterogeneity in MCV1 
























Fig. 1 | Estimated MCV1 coverage among districts in 101 LMICs, 2000–2019. 
a–c, MCV1 coverage among target population in districts in 2000 (a), 2010 (b) 
and 2019 (c). Countries excluded from the analysis and pixels classified as 
‘barren or sparsely vegetated’ based on European Space Agency Climate 
Change Initiative (ESA-CCI) satellite data or with fewer than 10 people per 
1 × 1-km2 pixel based on WorldPop estimates are masked in grey30,50.
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a Gini-coefficient-derived metric that ranges between zero (perfectly 
homogenous coverage) and one (perfectly heterogeneous coverage), 
at the 5 × 5-km2 level. In 2000, nine countries (Cameroon, Democratic 
Republic of the Congo, Guinea, India, Laos, Madagascar, Mali, Nigeria 
and Yemen) had high absolute geographical inequality (above 0.15). 
In 2019, only five countries had high absolute geographical inequal-
ity (Angola, Ethiopia, Madagascar, Nigeria and Pakistan). Nigeria had 
absolute geographical inequality above or equal to 0.2 in both 2000 and 
2019, and 25 countries had increased absolute geographical inequality 
in 2019 compared with 2000. Notably, absolute geographical inequal-
ity decreased considerably in India, from 0.23 in 2000 to 0.07 in 2019.
In general, and as expected, improvements in national-level coverage 
over time were accompanied by reductions in subnational absolute 
geographical inequality (Fig. 3). Changes in coverage were negatively 
correlated (ρ = −0.47, Pearson’s product moment test statistic = −5.36, 
P < 0.001) with changes in absolute inequality. India is a true exemplar in 
this trend, with sizeable reductions in inequality occurring as coverage 
increased. This improvement was not the only pathway for a country, 
however; some countries with increasing coverage also experienced 
increasing inequality, such as Chad and Ethiopia. Other countries 
experienced decreasing coverage alongside increasing inequality, 
such as Angola.
Coverage in urban and rural areas
In a post hoc analysis, we compared vaccination status in urban and 
remote rural settings, using proxies of travel time of ≤30 min and ≥3 h, 
respectively, to the nearest major city or settlement29 and the number 
of children under 5 years old30 from gridded estimates. In 2019, MCV1 
coverage was relatively lower in remote rural areas: in remote rural 
locations, 33.3% of children were MCV-unvaccinated, compared with 
15.2% of children living in urban areas. Owing to the concentration of 
populations in urban centres, however, more unvaccinated children 
lived in urban locations (47.9% of all unvaccinated children) than remote 
rural areas (16.0% of all unvaccinated children) in 2019, although this 
pattern varied across countries and regions (Fig. 4). For example, in 
Chad, 19.3% of unvaccinated children lived in urban locations and 44.4% 
lived in remote rural locations in 2019. In Mexico in 2019, 72.3% of unvac-
cinated children lived in urban locations and 3.4% lived in remote rural 
locations (Extended Data Fig. 10).
Our results show the variability of urban and rural contributions to 
unvaccinated populations in each country and region. In Latin America 
and the Caribbean, for example, MCV1 coverage is generally similar 
between urban and rural settings (Fig. 4); the urban–remote rural 
distribution of unvaccinated children therefore largely reflects the 
underlying population distribution. In other regions, the interaction 
between population and coverage is more complex. In South Asia, 
for example, 21 times more unvaccinated children live in urban loca-
tions compared with remote rural locations. Strategies focused solely 
on reaching the most unvaccinated children possible in that region, 
therefore, might reasonably prioritize urban areas. Overall, however, 
MCV1 coverage in urban areas of South Asia averages 90.7%, compared 
to only 77.4% in remote rural areas. Approaches that focus primarily on 
reaching urban areas, therefore, would probably exacerbate existing 
urban–rural coverage inequalities.
Discussion
Our MCV1 coverage estimates show overall progress from 2000 to 
2019, corresponding to the creation of benchmark targets from the 
Measles and Rubella Initiative and GVAP, as well as substantial financial 
support for comprehensive vaccination programming generated by 
the introduction of Gavi, the Vaccine Alliance5,6,31–34. Moreover, 62 out 
of 101 countries increased national-level MCV1 coverage while reduc-
ing subnational geographical inequalities over time, a noteworthy 
achievement.
This remarkable global progress should be celebrated, but this trend 
was not universal. Our results show a decline and stagnation in routine 
MCV1 coverage in certain locations, particularly since 2010, that may be 
related to conflict, vaccine scepticism, available funding support and 
supply disruptions35. Among countries with stagnant or declining cov-





























Fig. 2 | Estimated absolute changes in MCV1 coverage in the early (2000–
2010) and late (2010–2019) study periods. a, b, Mean district-level absolute 
differences in MCV1 coverage from 2000 to 2010 (a) and from 2010 to 2019 (b). 
Countries excluded from the analysis and pixels classified as ‘barren or 
sparsely vegetated’ based on ESA-CCI satellite data or with fewer than 10 
people per 1 × 1-km2 pixel based on WorldPop estimates are masked in grey30,50.
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ongoing political instability and conflict, which serve as major barriers 
to the success of vaccination programmes36–38. Supply disruptions also 
present a major barrier to achieving and sustaining high levels of MCV 
coverage. For example, in 2018, the Philippines reported a national-level 
MCV stockout39. The stockout, alongside waning public confidence in 
vaccination programmes stemming from misinformation related to 
risks of the Dengvaxia dengue vaccine, contributed to a national-level 
drop in coverage from 80% to 69% between 2017 and 201840. In Angola, 
economic turmoil led to a 28% decrease in governmental health spend-
ing per capita between 2010 and 2018, which may have also contrib-
uted to declines in vaccination coverage41. While global immunization 
initiatives have often focused on low-income countries, districts in 
middle-income countries also experienced recent declines, emphasiz-
ing the need for reliable immunization programmes and monitoring in 
these nations42. In Indonesia, for instance, 3 districts had coverage that 
reached 95% in 2000, increasing to 13 in 2010, but decreasing back to 
zero in 2019. In addition, countries with higher than average vaccine 
scepticism, such as Peru and Moldova, also experienced decreasing 
coverage rates and increasing within-country inequality43.
Overlaid on these persistent challenges, the ongoing COVID-19 pan-
demic has caused the cancellation of supplementary measles immuni-
zation campaigns and puts the delivery of critical routine immunization 
services at risk7,8. Baseline subnational estimates of routine MCV1 immu-
nization in LMICs can help to define the geographical areas of highest 
vulnerability to pandemic-associated disruptions. To mitigate the risk 
of measles outbreaks in the setting of the COVID-19 pandemic, the 
maintenance of routine immunization services is crucial44—particularly 
in areas with pre-existing routine immunization weaknesses.
Even before the current pandemic, few countries reached the GVAP 
target of 80% coverage in all districts by 2019. Stagnant progress 
between 2010 and 2019 further suggests that new approaches are 
needed to reach unvaccinated children and resolve geographical 
inequalities. As the era of GVAP draws to a close and the Immuniza-
tion Agenda 2030 begins, these results provide a platform to identify 
successes and inform strategies for the next decade. India, for instance, 
saw exemplary improvement in both national-level coverage and geo-
graphical equality over time. This may be attributable to specific inter-
ventions such as Mission Indradhanush, launched in 2014 with the goal 
of targeting underserved unvaccinated populations45. In addition, 
India introduced a second dose of MCV (MCV2) in select subnational 
geographies with MCV1 coverage below 80% starting in 2008, and 
expanded MCV2 to cover all districts in 2010 through the strengthening 
of both routine and supplementary immunization programmes46,47. The 
introduction of MCV2 into the national schedule may provide a second 
opportunity for first-dose vaccination among children who missed the 
scheduled MCV1 dose. Understanding the specific drivers of simultane-
ous coverage and equality gains may provide critical insights for the 
immunization agenda in countries and regions that have fallen behind.
The Equity Reference Group for Immunization highlights the need 
for increased attention on vaccinating vulnerable children who live in 
remote rural, urban poor and conflict settings, as well as for equality 
in coverage by gender48. These recommendations suggest that the 
agenda to leave no child unvaccinated, set by global partners and the 
Sustainable Development Goals, should transcend geography types 
and aim to eliminate coverage gaps among children who live in both 
urban and remote rural areas49. These geographically resolved MCV1 
estimates provide a tool for decision-makers to plan supplementary 
immunization activities and routine immunization strengthening 
programmes, to reach both the urban and remote rural communities 
where unvaccinated children live.
Despite large improvements made in MCV1 coverage from routine 
immunization programmes between 2000 and 2019, stalling pro-
gress and substantial subnational variation remain in many LMICs, 
leaving children at risk of preventable death. Policymakers should 
note where progress is most critically needed to successfully meet 
global immunization targets and protect the most-vulnerable children 
against measles. Our subnational estimates of routine MCV1 coverage 
at policy-relevant scales provide a tool for decision-makers to use in 
advocating for strong, sustainable immunization programmes that 
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Fig. 4 | Vaccination status in 2019 and geographical remoteness. 
Cumulative proportion of unvaccinated children living within the spectrum of 
the travel time (in hours) to a major city or settlement per region (left) and 
coverage among children living within the spectrum of travel time to a major 
city or settlement per region (right). Vertical dashed grey line shows thresholds 
for ‘urban’ and ‘remote rural’, living within 30 min and at least 3 h from a major 
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Fig. 3 | Absolute geographical inequality of MCV1 coverage in 2000 and 
2019. We compared the change in geographical absolute inequality to change 
in national-level coverage from 2000 to 2019. Points are sized by under-5 
population size.
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Methods
Data reporting
As this is a modelling study, no statistical methods were used to pre-
determine sample size, the experiments were not randomized and the 
investigators were not blinded to allocation during experiments and 
outcome assessment.
Overview
Building from our previous study of diphtheria–tetanus–pertussis vac-
cination coverage in Africa14, we fitted a geostatistical model with cor-
related errors across space and time to predict 5 × 5-km2 level estimates 
of MCV1 coverage from 2000 to 2019 using a suite of geospatial and 
national-level covariates for 101 LMICs. This overall process has been 
summarized in Extended Data Fig. 1. We spatially aggregated estimates 
using population-weighted averages to second administrative units 
from a modified version of the Database of Global Administrative Units 
(GADM), referred to as districts, and performed post hoc analyses to 
assess geographical inequality to examine progress towards GVAP 
targets, absolute geographical inequality and vaccination status as a 
function of geographical remoteness5. This study is compliant with the 
Guidelines for Accurate and Transparent Health Estimates Reporting 
(GATHER) recommendations51 (Supplementary Table 1).
We defined routine MCV1 coverage as evidence of receipt of at 
least one dose of a MCV from either a home-based record (HBR) or 
parental recall among the target population in concordance with 
country-specific vaccination schedules in 201952. Despite our best 
efforts to remove doses delivered through supplemental immunizion 
activities (SIAs) (Supplementary Information section 1.3.4), there is 
likely to be residual misclassification of some SIA doses due to the 
limitations of the available data, and these estimates of routine cover-
age should be viewed in the context of this limitation.
Countries were selected for this analysis if they were a LMIC or were a 
‘Decade of Vaccine’ priority country with available subnational survey 
data on MCV1 coverage between 2000 and 201953. We defined LMICs 
based on the socio-demographic index, a metric combining education, 
fertility and income to summarize development, as determined by 
GBD 201954. For 13 countries (Bhutan, Brazil, China, Dominica, Geor-
gia, Grenada, Libya, Oman, Palestine, Saint Lucia, Saint Vincent and 
the Grenadines, Seychelles and Venezuela), no available subnational 
vaccine coverage data met the inclusion and exclusion criteria; these 
countries were therefore excluded from this analysis. A full list of 
included countries is provided in Supplementary Table 3. Countries 
were assigned to one of 13 continuous geographical modelling regions. 
These regions were adapted from regions defined by GBD 2019, which 
are constructed to group countries together by epidemiological simi-
larity and geographical proximity (Extended Data Fig. 2).
Data
Using the Global Health Data Exchange (GHDx)55, we identified and 
compiled a total of 354 population-based household surveys from 
101 LMICs from 2000 to 2019 containing individual MCV1 vaccination 
status and subnational geolocation information. Surveys were included 
if they contained MCV1 coverage information and subnational geoloca-
tion, and excluded if they contained areal data and were missing key 
survey design variables (strata, primary sampling units and design 
weights), did not include children aged 12–59 months, contained no 
subnational individual-level geographical information or if coverage 
estimates were implausible (Supplementary Tables 4, 5).
Coverage was computed at the cluster level when global position-
ing system (GPS) data were available. If GPS information was not 
collected or was not available, we calculated mean coverage at the 
most-granular geographical area possible while accounting for sam-
pling weights and survey design. These aggregated coverage esti-
mates were then included in the geospatial modelling process using a 
previously described method14,56 that leverages population weights and 
a k-means clustering algorithm to propose a set of GPS coordinates as 
a proxy for locations where survey data collection could have occurred 
(Supplementary Fig. 3). These coordinates were then used to repre-
sent the areal data in the geospatial model. The following data were 
extracted from each survey source: vaccine card or HBR doses, parental 
recall vaccine doses, age (in months), survey weight and design vari-
ables, and GPS cluster or areal location. Individuals with evidence of 
vaccination either from HBR or recall were considered to have been 
vaccinated. Individuals were excluded from the analysis if they were 
missing age, spatial or survey design information or were outside of 
the study age or year range. The study included all years between 2000 
and 2019. A comprehensive overview of data from all study geographies 
included can be found in Supplementary Figs. 1, 2.
Individual age, in months, at the time of survey collection was used 
to assign each child to a birth cohort (12–23 months, 24–35 months, 
36–47 months and 48–59 months). Data corresponding to each birth 
cohort were included in the modelling process in the year in which that 
birth cohort was aged 0–12 months old. For countries recommending 
MCV1 within the first year of life, we included data from children aged 
12–47 months. If the first dose was not recommended until the second 
year of life, we included data from children aged 24–59 months. A full 
list of schedules by country can be found in Supplementary Table 2. This 
yielded a dataset of 1,697,570 total children. This method allows the 
inclusion of additional individuals, which increases overall geographi-
cal representation but requires assumptions such as negligible catch-up 
vaccination and no differential mortality or migration. However, the 
overall influence of including older cohorts in our model on the key find-
ings appeared to be minor (Supplementary Information section 2.2). 
Additional information on the benefits and limitations of this approach 
can be found in the Supplementary Information sections 1.3.4, 2.2, 
Supplementary Figs. 18–20 and Supplementary Tables 14, 15.
We included 26 geospatial covariates as possible predictors of MCV1 
coverage in the modelling process, including maternal education, 
access to major cities or settlements, a binary urban or rural indica-
tor, total population and a suite of 22 environmental covariates (Sup-
plementary Fig. 4 and Supplementary Table 6). Four national-level 
covariates were also included: lag-distributed income, prevalence of the 
completion of the fourth antenatal care visit among pregnant women, 
mortality due to war and terror, and bias-adjusted national-level admin-
istrative data on MCV1 coverage reported through the WHO/UNICEF 
Joint Reporting Form (Supplementary Information section 1.5.1). For 
each region, an optimized set of geospatial covariates was selected 
from these 26 possible covariates, using a variance inflation factor 
(VIF) algorithm57 in which covariates were selected with a VIF < 3. This 
method was used to ensure non-collinearity between covariates within 
each region to facilitate model convergence. Selected covariates varied 
by region (Supplementary Table 7).
Other spatial data used in our analyses included gridded population 
estimates, administrative boundaries and gridded estimates of travel 
time to major cities or settlements. These sources are described in 
detail in Supplementary Information section 1.3.
Geostatistical model
First, stacked generalization was used to capture potential nonlin-
ear and complex relationships between covariates and vaccination 
coverage. This approach has previously been shown to increase the 
predictive accuracy of geospatial models58. Using the optimized set of 
covariates selected for each region by the VIF algorithm, three differ-
ent child models—generalized additive models, lasso regression and 
boosted regression trees—were fit, with each model predicting MCV1 
coverage as the outcome of interest. When fitting boosted regression 
trees, country-level fixed effects were included to allow relationships 
between coverage and covariates to differ by country. In this initial 
modelling step, there were no explicitly defined temporal or spatial 
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effects included in the models beyond those inherently present in the 
covariate patterns and correlations between covariates.
Each child model was fit using fivefold cross-validation to avoid over-
fitting. This generated out-of-sample predictions of coverage for each 
location and year per region. Each model in each region was also fit 
using the full set of vaccine coverage outcome data, which yielded a cor-
responding set of in-sample predictions. The predictions of MCV1 cov-
erage obtained from each child model were in turn used as predictors in 
the second-step geostatistical model described below. Out-of-sample 
predictions from each child model were used as explanatory covari-
ates when fitting the geostatistical model. In-sample predictions from 
each model and region were used when generating predictions from 
the fitted geostatistical model.
After the first step (stacked generalization), a second-step Bayesian 
geostatistical modelling framework was used to model vaccination 
coverage as counts in a binomial space with a logit link through a gen-
eralized linear regression with explicit spatial and temporal terms. This 
second step leverages the covariate relationships estimated through 
stacked generalization while also accounting for additional correlation 
in coverage across space and time.
A separate model of MCV1 coverage was fit for each of the 13 regions 
as defined below:
∼C p N p N d| , Binomial( , )∀ observed clustersd i d t d d i d t d d( ), ( ) ( ), ( )
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This model, adopted from widely used Bayesian hierarchical 
models59,60, has been described in detail in other work14,25,56,61,62. In brief, 
this method estimates the number of children, C, in cluster d at location 
i and time t with sample size N that have been vaccinated with a specific 
antigen-dose combination. pi(d),t(d) is the proportion of children vac-
cinated with MCV1 among the target age population in cluster d. Each 
child model generates a prediction Xi,t for each child model h. Residual 
terms ϵ⁎ are unique to each particular location in space and time across 
all modelled geographies and years.
In this generalized linear regression framework, the proportion of 
children vaccinated pi,t is modelled using the out-of-sample predic-
tions of vaccine coverage Xi,t from each of three stacked generaliza-
tion child models (h) as explanatory variables. The βh coefficients are 
constrained to sum to 1, via the ‘extraconstr’ R-INLA parameter63, to 
improve computational tractability58 and are representative of the 
predictive weighting used in the stacking process.
ϵ icountry( ) represents a country-level random effect. ϵi t,  represents an 
independent nugget effect for irreducible error for a given observation, 
which accounts for true variation that is unable to be captured by the 
model and variation from measurement error. Zi,t represents a corre-
lated spatiotemporal error term, for any residual autocorrelation across 
space and time that remains after accounting for the predictive capac-
ity of the stacked-modelled covariates, country-specific variation in 
vaccine coverage and observation-specific irreducible error.
These additional spatiotemporal residuals Zi,t were modelled as a 
three-dimensional spatiotemporal Gaussian process with a mean of 
zero and a covariance matrix formed from the Kronecker product of 
spatial and temporal covariance kernels. The temporal covariance Σtime 
was modelled via an annual autoregressive order 1 function from all 
study years from 2000 to 2019, where ρ is the autocorrelation function 
and k and j are points in the annual time series. The spatial covariance 
Σspace was assumed to be an isotropic, stationary Matérn function, where 
Γ is the gamma function, Κv is the modified Bessel function of the sec-
ond kind of order v > 0, σspace
2  is the marginal variance, v is a scaling 
constant, δ is a range parameter with a penalized complexity prior, and 
D is a spatial distance matrix64, measured along the great circle in kilo-
metres. The generalized linear model was fitted using an integrated 
nested Laplace approximation in R-INLA with a stochastic partial dif-
ferential equation (SPDE) solver in package SPDE65. Additional detailed 
information on priors, spatial mesh construction and model fitting is 
provided in Supplementary Information sections 1.4.2–1.4.6 and Sup-
plementary Fig. 5. This process produces a set of 1,000 posterior draws, 
each representing an estimate of vaccine coverage for each location 
and year— in other words, a set of 1000 candidate maps of coverage 
from 2000 to 2019.
Post-estimation
To leverage data from additional national-level sources, including 
administrative data, and maintain internal consistency, the set of can-
didate maps was calibrated to MCV1 coverage estimates produced 
for GBD 2019. This post hoc calibration preserves the overall spatial 
variation of estimates, while ensuring that the population-weighted 
averages of the geospatial estimates are equivalent to those produced 
by GBD4. This step allows for the calibrated estimates to reflect infor-
mation from data sources that are only available at the national level, 
such as surveys for which no subnational data are available, which 
are included in the GBD estimates but excluded from the geospatial 
model described in the ‘Geostatistical model’ section. A description 
of the estimation of MCV1 coverage for GBD 2019 can be found in Sup-
plementary Information section 1.5.1.
In this calibration process, each 5 × 5-km2 pixel in each modelled 
region was first assigned to a second-level administrative unit. In loca-
tions in which boundary definitions transect a given pixel, the frac-
tion of area of that pixel belonging to each overlapping second-level 
administrative unit was calculated. Because of the nested hierarchy 
of administrative units, this additionally allowed for the assignment 
of pixels and partial pixels to first administrative units and countries. 
Assuming that the population density within each pixel was uniform, 
WorldPop population values of children under 5 years old were divided 
for each whole or partial pixel proportional to fractional area. After 
pixel and partial pixel populations were assigned, population-level 
estimates were calibrated to GBD population estimates for each coun-
try and year.
Calibration methods similar to those used in this study have 
been described previously14. To ensure vaccination coverage esti-
mates post-calibration remained between 0 and 100%, calibra-
tion was performed in logit space such that for each country c 
and year t, national-level estimates of coverage from GBD (VGBD,c,t) 
and population-weighted national averages of coverage from the 
model-based geostatistical (MBG) model (VMBG,c,t) can be related via a 
country-year-specific calibration factor (kc,t) in the following equation:
V V klogit( ) = logit( ) +c t c t c tGBD, , MBG, , ,
Calibration factors were applied to each 5 × 5-km2 pixel and partial 
pixel per draw per country-year. Pixels that were fractionally assigned 
to multiple countries were combined using a weighted average pro-
portional to the fraction of each area. This process resulted in a set of 
calibrated draw-level estimates of vaccination coverage, which were 
used for all subsequent analyses.
Population-weighted averages of coverage for each pixel or partial 
pixel within a first or second administrative unit were then calculated. 
Fractional pixel membership was determined as described above. This 
process was repeated for each of the 1,000 posterior pixel-level draws, 
which yielded 1,000 posterior draws of MCV1 coverage per administra-
tive unit per year. Estimates for first and second administrative units 
with uncertainty were derived from mean, 2.5th and 97.5th percentiles.
Model validation
We assessed the predictive performance of the models using fivefold 
out-of-sample cross-validation. We stratified data by first and second 
administrative units and ran models leaving out one-fifth of the spatially 
stratified data at a time. Predicted estimates of MCV1 coverage were 
then compared to the withheld observed data by calculating the mean 
error, root mean square error, correlation and other predictive validity 
metrics for all years for which survey data were available (2000–2018). 
Fitted model parameters can be found in Supplementary Table 8. Met-
rics and validity figures can be found in Supplementary Tables 9–12 
and Supplementary Figs. 6–13, respectively. Additional information 
regarding uncertainty of estimates can be found in Supplementary 
Figs. 14–17.
Post hoc geospatial inequality analyses
Lorenz curves were generated using the relationship between the 
number of children and the number of vaccinated children for each 
pixel. Pixel-level Gini coefficients were calculated for 2000 and 2019 
from corresponding Lorenz curves66,67 (Supplementary Table 13). 
Absolute geographical inequality per country was calculated from 
the national-level Gini coefficients and national MCV1 coverage using 
the following formula:
Absolute geographical inequality = 2 × coverage × Gini
We chose to use the absolute geographical inequality metric to rep-
resent inequality over the Gini coefficient alone. As the mean is related 
to Gini, we wanted to account for this relationship. Estimates are scaled 
by 2 as this puts the absolute geographical inequality coefficient back 
to the same scale as the mean68.
Additionally, we assessed vaccination status as a function of geo-
graphical remoteness. Using a gridded surface of travel time to major 
cities or settlements, we classified each 5 × 5-km2 pixel as remote rural, 
urban or neither29. Pixels with travel times of less than 30 min were 
classified as urban, and pixels with travel times greater than 3 h were 
classified as remote rural. Overlaid with a gridded population surface 
from WorldPop30, the number of unvaccinated children per pixel was 
also calculated.
We constructed concentration curves of the cumulative proportion 
of unvaccinated children as well as plots of MCV1 coverage by travel 
time to assess patterns across countries and regions. Country-specific 
concentration curves of the cumulative proportion of unvaccinated 
children as a function of travel time for select countries are shown in 
Extended Data Fig. 10. Summary metrics, such as the proportion of 
unvaccinated individuals living in each urban and remote rural loca-
tion, were computed.
Limitations
This work is subject to several limitations. First, the primary data used 
in this analysis came from child-level survey data with varying degrees 
of representativeness, consistency, accuracy and comparability, from 
both HBR and parental recall69,70. The magnitude and direction of recall 
bias varies, and we therefore were unable to correct for it71. We estimate 
coverage using data from children aged 12–59 months, and while we 
accounted for target age at vaccination, this does not fully account 
for differential mortality due to vaccine status or catch-up vaccina-
tion. We aim to estimate routine coverage and have excluded doses 
delivered via SIAs from the analysed survey data wherever possible 
(Supplementary Information section 1.3.4), but misclassification of SIA 
doses is still likely, particularly in cases of parental recall—especially 
for older children—and in cases in which survey methodology does not 
distinguish clearly between SIA and routine doses.
In data-sparse areas for which covariate relationships may not fully 
capture coverage patterns, results may be biased. Additionally, data 
representativeness among vulnerable populations, such as those living 
in urban slums or migrant populations, might vary due to data collec-
tion in survey design. We include as much data on MCV1 coverage as 
possible, including data that are only geo-resolved to areal locations. 
The methodology that we used to assign areal data to specific locations 
for modelling could lead to oversmoothing in final estimates, obscure 
relationships between coverage and covariates, and underestimate 
uncertainty, but this method has been shown to have a higher predic-
tive validity compared with the exclusion of the data72. Limitations due 
to data availability should not be taken lightly and should reinforce 
to stakeholders and policymakers the need for additional resources 
to collect high-quality data that are representative of all populations, 
especially the most vulnerable for being unvaccinated, and to increase 
the quality of routinely collected subnational administrative data.
Because the estimates that we used to assess geographical remote-
ness in post hoc analyses were also used as spatial covariates in the 
geospatial model, these results are limited by the possibility of cir-
cularity and subsequent confounding. In addition, we used a stacked 
generalization method to allow for complex and nonlinear relation-
ships between covariates and vaccination coverage. These methods 
are optimized for prediction, not causal inference. For that reason, 
these results cannot be used to identify the specific effect of any par-
ticular covariate on MCV1 coverage. In addition, owing to limitations 
in the underlying data and computational feasibility, we were unable 
to incorporate several potentially important sources of uncertainty 
into this analysis, including from covariates, population estimates, 
the incorporation of areal data and the stacked generalization process.
We fitted our geostatistical models using R-INLA, as opposed to a 
full Markov chain Monte Carlo sampler. Although using a more tradi-
tional Bayesian model fitting approach that takes true samples from 
the posterior typically results in increased parameter identifiability, 
the Laplace approximation approach used by R-INLA is more computa-
tionally feasible given our current modelling scale. Our model is sepa-
rable, yet symmetric, across time and space. This approach assumes 
that, for each region, the covariance has the same functional form 
between years and locations regardless of the locations themselves; the 
use of a non-separable covariance function could relax these assump-
tions73,74. However, owing to the additional computational challenges 
associated with fitting a non-separable model, as well as data sparsity 
in several regions throughout space and time, we determined that fit-
ting a non-separable model would be challenging and complex, and 
would probably yield little benefit compared to our current modelling 
approach.
In some settings with high levels of natural immunity (derived from 
previous infection), greater than 95% vaccination coverage may not 
be required to prevent disease transmission75. These estimates only 
focus on the first routine dose of MCV, and immunity can also be 
obtained through later vaccination via SIA or natural infection. In an 
ideal long-term measles elimination scenario, all immunity would be 
vaccine-derived, and no natural infections would occur. A 95% cov-
erage target for routine immunization, therefore, still has practical 
programmatic relevance.
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Finally, our study describes spatial heterogeneity in coverage, but not 
pockets of low coverage within social or age groupings that can facili-
tate ongoing disease transmission, particularly in densely populated 
areas, despite nominally high average vaccine coverage76. Although 
these results provide a powerful tool for policymakers to identify weak-
nesses in routine immunization systems and plan for SIA, they should 
be used in conjunction with other data sources that can be used to make 
decisions about vaccine policy, including analyses of cost effectiveness, 
determinants of high or low coverage, and specific coverage initiatives 
to reduce disease burden.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
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Extended Data Fig. 1 | Data processing and geospatial modelling flowchart. 
Survey data and the suite of covariates used in modelling are first compiled and 
processed (orange and grey). The modelling process (purple) consists of data 
being used in a stacked generalization ensemble modelling process via 
boosted regression tree, lasso and generalized additive models, fitting the 
second-stage spatiotemporal model using integrated nested Laplace 
approximation, and finally calibration to GBD estimates (blue). Steps in dark 
green and outputs in yellow indicate the post-estimation process when the full 
posterior distribution of predications is transformed to both 5 × 5-km2 and first 
and second administrative-unit-level maps and their various final results. 
Intermediate outputs throughout the process are shown in blue and overall 
processes are shown in light green.
Extended Data Fig. 2 | Regions of countries used in modelling. Analyses 
were divided into 13 regions based on the GBD super-regions to allow for 
locations similar in data availability and patterns of vaccine coverage to be 
analysed using similar covariate and modelling relationships. Each colour 
represents a different region, as described in the legend.
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Extended Data Fig. 3 | National, first- and second-administrative-unit level, 
and pixel-level MCV1 coverage, 2000. a–d, Posterior means are represented 
at the national (a), first-administrative-unit (b), second-administrative-unit (c) 
and 5 × 5-km2 pixel (d) levels. Pixels that are grey in colour are either not 
included in the analysis, or have been classified as being ‘barren or sparsely 
vegetated’ or had fewer than 10 people per 1 × 1-km2 pixel30,50.
Extended Data Fig. 4 | National, first- and second-administrative level, and 
pixel-level MCV1 coverage, 2005. a–d, Posterior means are represented at the 
national (a), first-administrative-unit (b), second-administrative-unit (c) and 
5 × 5-km2 pixel (d) levels. Pixels that are grey in colour are either not included in 
the analysis, or have been classified as being ‘barren or sparsely vegetated’ or 
had fewer than 10 people per 1 × 1-km2 pixel30,50.
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Extended Data Fig. 5 | National, first- and second-administrative-unit level, 
and pixel-level MCV1 coverage, 2010. a–d, Posterior means are represented 
at the national (a), first-administrative-unit (b), second-administrative-unit (c) 
and 5 × 5-km2 pixel (d) levels. Pixels that are grey in colour are either not 
included in the analysis, or have been classified as being ‘barren or sparsely 
vegetated’ or had fewer than 10 people per 1 × 1-km2 pixel30,50.
Extended Data Fig. 6 | National, first- and second-administrative-unit level, 
and pixel-level MCV1 coverage, 2015. a–d, Posterior means are represented at 
the national (a), first-administrative-unit (b), second-administrative-unit (c) 
and 5 × 5-km2 pixel (d) levels. Pixels that are grey in colour are either not 
included in the analysis, or have been classified as being ‘barren or sparsely 
vegetated’ or had fewer than 10 people per 1 × 1-km2 pixel30,50.
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Extended Data Fig. 7 | National, first- and second-administrative-unit level, 
and pixel-level MCV1 coverage, 2019. a–d, Posterior means are represented at 
the national (a), first-administrative-unit (b), second-administrative-unit (c) 
and 5 × 5-km2 pixel (d) levels. Pixels that are grey in colour are either not 
included in the analysis, or have been classified as being ‘barren or sparsely 
vegetated’ or had fewer than 10 people per 1 × 1-km2 pixel30,50.
Extended Data Fig. 8 | Probability of increased or decreased coverage from 2000 to 2010 and 2010 to 2019. a–d, Probability of an increase in coverage in each 
district (a, b) and probability of decrease in coverage in each district (c, d) from 2000 to 2010 (a, c) and 2010 to 2019 (b, d).
Article
Extended Data Fig. 9 | Estimated district-level probabilities of reaching 
MCV1 coverage targets in 2019. a, b, Probability of districts having achieved 
80% GVAP and Measles Rubella Initiative targets (a) and 95% critical proportion 
to immunize coverage targets to reach herd immunity (b). Countries excluded 
from the analysis and pixels classified as ‘barren or sparsely vegetated’ based 
on ESA-CCI satellite data or with fewer than 10 people per 1 × 1-km2 pixel based 
on WorldPop estimates are masked in grey30,50.
Extended Data Fig. 10 | Country examples of concentration curves. Concentration curves of the cumulative proportion of unvaccinated children as a function 
of travel time (in hours) in Chad (a), Madagascar (b), India (c) and Mexico (d). Curves for both the indicated countries (blue) and all LMICs (grey) are shown.
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